Barbara Bumstead

发表

The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis

G. Doniger, I. Lavi, M. Gudesblatt, 2018, Multiple sclerosis.

An investigation into the Relationship between the Multiple Sclerosis Impact Scale (MSIS-29) and Predicted Medication Adherence as Measured by the Morisky Medication Adherence Scale (MMAS-8) in People with Multiple Sclerosis (P4.373)

D. Morisky, M. Gudesblatt, Karl Wissemann, 2018 .

Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis

C. Hotermans, M. Gudesblatt, Karl Wissemann, 2018, CNS Drugs.

Individual differences in visual evoked potential latency are associated with variance in brain tissue volume in people with multiple sclerosis: An analysis of brain function-structure correlates.

Thomas J. Covey, W. van Hecke, D. Sima, 2022, Multiple sclerosis and related disorders.

Prolonged visual evoked potential latency predicts longitudinal worsening of fatigue in people with multiple sclerosis.

Thomas J. Covey, G. Doniger, M. Gudesblatt, 2022, Multiple sclerosis and related disorders.

Measuring cognitive function by the SDMT across functional domains: Useful but not sufficient.

Thomas J. Covey, G. Doniger, I. Penner, 2022, Multiple sclerosis and related disorders.

Visual evoked potential latency predicts cognitive function in people with multiple sclerosis

Thomas J. Covey, G. Doniger, M. Gudesblatt, 2021, Journal of Neurology.

The relationship between cognitive impairment, cognitive fatigue, and visual evoked potential latency in people with multiple sclerosis.

Thomas J. Covey, G. Doniger, M. Gudesblatt, 2021, Multiple sclerosis and related disorders.

Validity of a multi-domain computerized cognitive assessment battery for patients with multiple sclerosis.

G. Doniger, R. Kane, M. Gudesblatt, 2019, Multiple sclerosis and related disorders.

Cognitive impairment, fatigue and depression in multiple sclerosis: Is there a difference between benign and non-benign MS?

Thomas J. Covey, S. Morrow, J. Halper, 2023, Multiple sclerosis and related disorders.

Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.

Thomas J. Covey, M. Gudesblatt, D. Golan, 2023, Journal of neurology.

Variability of objective gait measures across the expanded disability status scale in people living with multiple sclerosis: A cross-sectional retrospective analysis.

Thomas J. Covey, Edward Ofori, J. Sosnoff, 2022, Multiple sclerosis and related disorders.

The moderating roles of self-efficacy and depression in dual-task walking in multiple sclerosis: A test of self-awareness theory

Thomas J. Covey, Edward Ofori, D. Peterson, 2022, Journal of the International Neuropsychological Society.

De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate

D. Golan, Myassar Zarif, Barbara Bumstead, 2024, Advances in therapy.

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Barbara Bumstead, S. Wray, J. Lewin, 2024, Neurology and therapy.